Dallas, TX – (WiredPRNews.com) MesotheliomaWeb.Org is a valued resource for educational information, serving patients dealing with mesothelioma and other diseases associated with asbestos exposure. Mesothelioma is a form of cancer that affects the cells that surround the lungs and other vital organs. MesotheliomaWeb.Org offers visitors the most recent news on research efforts, treatment techniques, and more news and information on this lethal disease. The aim of this web site is to boost awareness pertaining to diseases related to asbestos exposure, in addition to the attempts to care for and aid patients afflicted by mesothelioma.
Researchers in Australia have made an important stride in bettering the quality of life for patients diagnosed with mesothelioma. However, these scientists also state that the country has yet to reach its highest incidence rate of this fatal form of lung cancer. In recent years, scientists have concluded that mesothelioma is often induced by exposure to asbestos. The disease is typically lethal within eighteen to twenty-four months of receiving a diagnosis, although many patients will perish within just a few months, in spite of receiving the best treatments available.
At the Bernie Banton Centre in Sydney, Australia, scientists with the Asbestos Diseases Research Institute (ADRI) have developed a blood test that indicates a mesothelioma patient’s survival prognosis. The test measures the ratio of two biomarkers in the blood: lymphocytes and neutrophils.
Professor Nico van Zandwijk, director of the ADRI, said that the test would help “to individualize treatment approaches”. Until recently, most mesothelioma patients received similar treatment routines of surgery, chemotherapy and radiation therapies.
Professor van Zandwijk said patients with “a poor prognostic profile” would cause doctors “to be very careful” with their plans for major surgery or other radical treatments. He also said that the blood tests would determine which patients would have a higher tolerance for a “more intense treatment”.
Researchers on the project will also continue further study into how these and other biomarkers can determine the correct course of treatment for mesothelioma patients. For instance, one avenue of research could uncover biomarkers that would indicate the effectiveness of different types of chemotherapy treatments in an individual patient.
Another proposed idea would be a blood test to diagnose the disease in its early stages. Currently, most patients do not receive a diagnosis until the disease has progressed much further. Many patients exposed to asbestos are not diagnosed until decades after the initial exposure period.
One report shows that more than five hundred Australians die from mesothelioma every year, a rate of nearly ten per week. Professor van Zandwijk predicted that, as to the growing incidence of the disease in the country, “We haven’t seen the peak yet”. He noted that asbestos was prevalent in many houses and other structures built in Australia from the 1940s to the 1980s.
He also said that the country must be “very careful” to prevent a new wave of mesothelioma in the upcoming years. “We are a little uncertain about the peak,” he told reporters. “Awareness in Australia is not yet optimal.”
For more information, please visit our website at www.mesotheliomaweb.org.